Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase I Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

Summary

NOTE: This trial is currently enrolling in Part I. The purpose of this phase II study is to evaluate the safety and efficacy of palbociclib in combination with gedatolisib in patients with advanced solid tumors, including pancreatic cancer.

General Information

NCT#: NCT03065062
Study ID: 16-499
Trial Phase: Phase I

Trial Sponsor: Pfizer, Dana-Farber Cancer Institute
Therapies Used in This Trial: Gedatolisib, Palbociclib

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search